P
26.34
-0.37 (-1.39%)
| Previous Close | 26.71 |
| Open | 26.75 |
| Volume | 1,465,461 |
| Avg. Volume (3M) | 1,604,887 |
| Market Cap | 2,270,814,976 |
| Price / Earnings (TTM) | 42.48 |
| Price / Earnings (Forward) | 12.05 |
| Price / Sales | 1.74 |
| Price / Book | 3.73 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | 4.33% |
| Operating Margin (TTM) | 7.46% |
| Diluted EPS (TTM) | 0.570 |
| Quarterly Revenue Growth (YOY) | 16.50% |
| Quarterly Earnings Growth (YOY) | -10.90% |
| Total Debt/Equity (MRQ) | 6.19% |
| Current Ratio (MRQ) | 2.39 |
| Operating Cash Flow (TTM) | 203.18 M |
| Levered Free Cash Flow (TTM) | 200.38 M |
| Return on Assets (TTM) | 5.99% |
| Return on Equity (TTM) | 10.11% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Bearish |
| Health Information Services (Global) | Bearish | Bearish | |
| Stock | Progyny, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.6
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | -0.63 |
|
Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 7.64% |
| % Held by Institutions | 98.36% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 32.00 (Keybanc, 21.49%) | Buy |
| Median | 29.00 (10.10%) | |
| Low | 26.00 (Canaccord Genuity, -1.29%) | Hold |
| 26.00 (JP Morgan, -1.29%) | Hold | |
| Average | 28.60 (8.58%) | |
| Total | 3 Buy, 2 Hold | |
| Avg. Price @ Call | 25.63 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citizens | 20 Jan 2026 | 30.00 (13.90%) | Buy | 25.38 |
| Keybanc | 08 Jan 2026 | 32.00 (21.49%) | Buy | 27.43 |
| 12 Nov 2025 | 30.00 (13.90%) | Buy | 24.07 | |
| Barclays | 09 Dec 2025 | 29.00 (10.10%) | Buy | 24.72 |
| Canaccord Genuity | 17 Nov 2025 | 26.00 (-1.29%) | Hold | 26.82 |
| JP Morgan | 11 Nov 2025 | 26.00 (-1.29%) | Hold | 23.81 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | Progyny to Discuss Updated Financial Expectations at Upcoming JP Morgan Healthcare Conference |
| 20 Nov 2025 | Announcement | New Men’s Health Research from Progyny Challenges Conventional Beliefs about Fertility Knowledge and Action |
| 13 Nov 2025 | Announcement | Progyny, Inc. to Present at Jefferies Global Healthcare Conference |
| 06 Nov 2025 | Announcement | Progyny, Inc. Announces Third Quarter 2025 Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |